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a b s t r a c t
Background and purpose: To quantify the indication for adaptive, gated breath-hold (BH) MR-guided
radiotherapy (MRgRTBH) versus BH or free-breathing (FB) CT-based image-guided radiotherapy (CTIGRT) for the ablative treatment of adrenal malignancies.
Materials and methods: Twenty adrenal patients underwent adaptive IMRT MRgRTBH to a median dose of
50 Gy/5 fractions. Each patient was replanned for VMAT CT-IGRTBH and CT-IGRTFB on a c-arm linac. Only
CT-IGRTFB used an ITV, summed from GTVs of all phases of the 4DCT respiratory evaluation. All used the
same 5 mm GTV/ITV to PTV expansion. Metrics evaluated included: target volume and coverage, conformality, mean ipsilateral kidney and 0.5 cc gastrointestinal organ-at-risk (OAR) doses (D0.5cc). Adaptive
dose for MRgRTBH and predicted dose (i.e., initial plan re-calculated on anatomy of the day) was performed for CT-IGRTBH and MRgRTBH to assess frequency of OAR violations and coverage reductions for
each fraction.
Results: The more common VMAT CT-IGRTFB, with its significantly larger target volumes, proved inferior
to MRgRTBH in mean PTV and ITV/GTV coverage, as well as small bowel D0.5cc. Conversely, VMAT CTIGRTBH delivered a dosimetrically superior initial plan in terms of statistically significant (p  0.02)
improvements in target coverage, conformality and D0.5cc to the large bowel, duodenum and mean ipsilateral kidney compared to IMRT MRgRTBH. However, non-adaptive CT-IGRTBH had a 71.8% frequency of
predicted indications for adaptation and was 2.8 times more likely to experience a coverage reduction in
PTV D95% than predicted for MRgRTBH.
Conclusion: Breath-hold VMAT radiotherapy provides superior target coverage and conformality over
MRgRTBH, but the ability of MRgRTBH to safely provide ablative doses to adrenal lesions near mobile luminal OAR through adaptation and direct, real-time motion tracking is unmatched.
Ó 2021 The Authors. Published by Elsevier B.V. Radiotherapy and Oncology 166 (2021) 101–109 This is an
open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Ablative stereotactic body radiotherapy (SBRT) has been
demonstrated to be a promising treatment for unresectable adrenal metastases [1–3]. Additionally, a higher biologically effective
dose (BED10, a/b = 10) is associated with significant increases in
local control and overall survival [1,4,5]. For BED10 values of
60 Gy, 80 Gy, and 100 Gy, a recent meta-analysis by Chen et al. predicted 2-year local control (LC) rates of 47.8%, 70.1%, and 85.6% and
overall survival (OS) rates of 34.0%, 47.2% and 60.1% [1]. However,
delivering ablative dose to the entirety of the target is often compromised by overlapping organs at risk (OAR) [6,7], which may be
exacerbated by the larger target volume required to encompass the
full motion envelope with respiration. Currently, the role of motion
⇑ Corresponding author at: Department of Radiation Oncology, Miami Cancer
Institute, Baptist Health South Florida, 8900 N Kendall Dr., Miami, FL 33176, USA.
E-mail address: kathrynm@baptisthealth.net (K.E. Mittauer).

management on the resulting dose distribution for adrenal SBRT is
unclear.
The same meta-analysis revealed that the most common
method of respiratory motion management for adrenal SBRT is free
breathing, internal target volume (ITV) contouring through fourdimensional computed tomography (4DCT) [1]. De Kuijer et al.,
in a limited series of 11 patients, quantified the motion of adrenal
glands between breath hold (BH) and free breathing (FB) on 4DCT
and found an overall reduction in the target volume favoring the
use of BH [8]. A clinical extrapolation of this premise is that the
reduction of target volume may enable dose escalation to a large
volume of the tumor for adrenal SBRT, which may potentially
improve long-term local control [1,4].
Magnetic resonance guided radiotherapy (MRgRT), using the
MRIdian Linac (ViewRay Inc., Oakwood, OH, USA), enables breath
hold motion management through direct real-time soft tissue

https://doi.org/10.1016/j.radonc.2021.11.024
0167-8140/Ó 2021 The Authors. Published by Elsevier B.V.
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and a 4DCT for respiratory evaluation on a SOMATOM Definition
Edge (Siemens Healthcare, Forchheim, Germany).
Segmentation of the gross tumor volume (GTV) was performed
by a disease site-specialized radiation oncologist on the BH MR
planning scan. In all cases, the planning target volume (PTV) was
defined by an isotropic 5 mm expansion of the GTV. Because the
patients were to receive gated BH delivery, no ITV was defined
for the MRgRT plan. OAR segmentation included large and small
bowel, stomach, duodenum, liver, spinal cord and both kidneys.
All contours were peer-reviewed prior to treatment.

tracking of the gross disease, without the need for surrogate
anatomical tracking, implanted fiducials, tidal-volume spirometry,
or external markers, as may be warranted in CT-based imageguided radiotherapy (IGRT) systems [9–11]. Consequently, the
use of MRgRT with BH may be an effective strategy to minimize
target volume and thereby reduce OAR dose, while maintaining
or improving tumor coverage.
Additionally, MRgRT provides the ability to perform daily online adaptation [6,9,12]. Palacios et al. demonstrated that stereotactic MR-guided adaptive radiation therapy (SMART) for adrenal
metastases allows target dose escalation and simultaneous gastrointestinal (GI) OAR sparing [6]. While their work quantified
the dosimetric indications for adaptation for adrenal metastases,
it did not quantify the dosimetric differences between MRguided real-time breath-hold tracking compared to the standard
CT-based free breathing strategies. Reports of other abdominal
and thoracic sites have demonstrated the dosimetric advantages
of a reduction in dose to the surrounding normal tissues in BH
compared to FB plans [8,13–15].
The purpose of this study is to quantitatively evaluate the indication for mid-inspiration breath-hold MR-guided radiotherapy
compared to the standard treatment technique of CT-based image
guided radiotherapy in the stereotactic ablation of adrenal malignancies. To the best of our knowledge, this is the first study to quantify both the indication for adaptation and the differences between
breath-hold MRgRT and free-breathing/breath-hold CT-IGRT for
adrenal lesions, using previously obtained clinical imaging.

MRgRTBH planning and treatment
Patients were prescribed a median dose of 50 Gy (n = 6 at 40 Gy,
n = 14 at 50 Gy) in 5 fractions to at least 99% of the GTV and 95% of
the PTV. The median BED10 value was 100 Gy (72 Gy for the 40 Gy
in 5 fractions treatments). A standardized institutional treatment
planning approach was used for all MRgRTBH plans and will be
briefly summarized here. Full target coverage was not always possible while still respecting OAR constraints, so a 3 mm margin was
generated around the GI OARs to create a planning organ-at-risk
volume (PRVGI). Optimized target volumes (PTVopt and GTVopt)
were created from the physician’s delineated PTV and GTV and
truncated at the edges of this PRVGI during planning. PTVopt and
GTVopt were optimized to the prescription dose, while the overlapping OARs were constrained to their maximum allowed limits
according to the treatment planning directive. Plan quality was driven until either full PTV and GTV coverage was achieved or until
maximum tolerance was reached for a single OAR. A 3 to 5 mm
contraction of the GTVopt was driven to a minimum of 120% of
the prescription dose, with a maximum point dose of 135–140%,
to provide an ablative hotspot to the center of the adrenal tumor
without increasing the dose gradient near the OARs. In order to
control low dose conformality, the 50% isodose volume was constrained to fall within the confines of a 1 cm thick shell, created
from isotropic 2 and 3 cm expansions of the PTVopt.
Table A2 (Appendix) provides an overview of the OAR constraints used for the patients included in this study. While the
majority of patients had both a maximum dose to 0.5 cc (D0.5cc)
and maximum dose to 0.03 cc (D0.03cc) for the bowel OARs, few
patients had D0.03cc constraints for the other GI OARs. Of note, a
range of OAR constraints are shown in Table A2, due to the enrollment of a subset of patients on clinical trials with differing OARs
constraints.
Treatment plans were step-and-shoot IMRT with beam arrangements generally spaced unilaterally (i.e., 200 degrees, n = 12 plans)
around the target with avoidance sectors for entrance beams
within 2 cm of patient arms or couch edges. The remaining
patients (n = 8 plans) were treated approximately isotropically
with similar avoidance structures. The number of beams ranged
from 12 to 21 (median 17). The number of segments was between
27 and 77 (median 46). Electron density for the calculation of dose
on the MR scan was provided by deformable registration of the BH
CT to the BH MR scan [16]. Manual electron density corrections
were included when necessary. Dose was calculated with a Monte
Carlo algorithm to
an
isotropic grid
resolution of
2 mm  2 mm  2 mm, including magnetic field corrections.
All patients underwent daily online adaptation. For daily MR
guidance, patient localization was achieved through alignment of
the GTV on the daily fractional 3D MR setup scan. Targets were
rigidly copied from the MR simulation scan to the MR of the day,
while OARs were deformably registered to the MR of the day frame
of reference. The GTV was manually edited to account for target
deformations and the PTV was manually re-expanded. OARs were
manually edited within 2 cm axially and 3 cm superior-inferior
of the PTV surface. The initial treatment plan was recalculated on

Materials and methods
Study overview
Twenty patients, at a single institution, were treated with midinspiration BH MR-guided radiotherapy to a median dose of 50 Gy
in 5 fractions for stereotactic ablation of adrenal metastases. A
summary of patient characteristics is provided in Table A1. Most
patients had adrenal metastases resulting from adenocarcinoma
of the lung (n = 12). The patients were evenly divided by sex, with
a slightly larger number of left adrenal lesions (n = 11) than right
(n = 9).
An overview of the study methods is presented in Fig. 1. In this
institutional review board (IRB) approved study, there are three
arms: breath-hold step-and-shoot IMRT MR-guided radiotherapy
(MRgRTBH), breath-hold VMAT CT-based image-guided radiotherapy (CT-IGRTBH), and free-breathing VMAT CT-based imageguided radiotherapy (CT-IGRTFB). The indication for FB (CTIGRTFB) versus gated BH delivery (MRgRTBH) was evaluated
through the dosimetric differences in target volume, gastrointestinal luminal organs, and ipsilateral kidney. To isolate the impact of
FB versus BH in the change from IMRT to VMAT, we assessed the
initial CT-IGRTBH plans compared to MRgRTBH. Lastly, we investigated the effects of daily MR adaptation versus non-adaptive CTIGRTBH by registering the initial CT-IGRTBH plans (approximated
on the simulation MRI) to the daily setup MR scans to quantify
the predicted dose for the CT-IGRTBH arm.
MRgRTBH simulation and segmentation
Patient simulation was performed in the supine position with
the ipsilateral arm raised over the head, except for a few instances
where patient tolerance dictated that both arms be down at their
sides. No immobilization was required for simulation due to the
use of real-time intrafraction MR tracking. A planning 0.35T, 3D
mid-inspiration breath hold (BH), true fast imaging with steadystate free precession (TrueFISP) MR scan was acquired on the MRIdian Linac followed by a BH CT for electron density information
102
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Fig. 1. Overview of study methods.

The CT-IGRTFB plans were calculated on the average intensity
projection (AIP) CT constructed from the 4DCT performed during
MRgRTBH respiratory evaluation. OAR segmentation was also done
on the AIP-CT by a board-certified medical physicist, with visual
reference to the corresponding OARs done for MRgRTBH. A
disease-site specialized radiation oncologist reviewed, edited, and
approved all normal OAR segmentation. The same radiation oncologist segmented the GTV on each phase of the 4DCT, which was
then summed to define the ITV. A uniform 5 mm expansion from
the ITV was used to create the PTV, equivalent to the PTV expansion used on MRgRTBH. The ITV and the OAR segmentation were
each peer-reviewed by a second disease-site specialized radiation
oncologist.

(180°) ipsilateral arcs proved insufficient to provide target coverage to the medial edges of the PTV, so most patients were treated
by beams that extended 45° over the anterior thorax (i.e., 225°).
Two of the patients, with very large PTVs (volume > 150 cc), were
treated to larger angles. Because some patients had both arms at
their sides during MRgRTBH simulation, avoidance sectors were
used to prevent entrance doses to their limbs. The net active arc
lengths for the CT-IGRTFB treatments ranged from 166° to 319°
(median 224°).
The CT-IGRTFB ITV and PTV were planned to the same 40–50 Gy
doses with the same 99% and 95% minimum coverage requirements
as the corresponding MRgRTBH GTV and PTV, with the same stipulation that the OAR constraints had to be met. The targets were
truncated to an ITVopt and PTVopt if overlapped with the PRVGI. To
mirror the MRgRTBH technique, CT-IGRTFB optimization was performed until either full PTV and ITV coverage was achieved or until
maximum tolerance was reached for a single OAR. A 3–5 mm contraction of the ITVopt was driven to a minimum of 120% of the prescription dose, with a maximum point dose between 130% and
140%, so that hotspots would fall in the center of the adrenal tumor
without excessive dose gradients near sensitive OARs. The 50% isodose volume was again constrained to fall within the limits of the
2–3 cm shell around the PTV, to ensure low dose conformality.
Two disease-site specialized radiation oncologists approved each
of the CT-IGRTFB plans which were never used in treatment.
Because daily 4DCTs were not performed, the CT-IGRTFB arm could
not be evaluated for the indication for adaptation.
For comparison to the MRgRTBH, the treatment times for CTIGRT were approximated. Since abdominal SBRT are triaged to
MRgRT and are not generally treated on a c-arm linac, the median
treatment time for the CT-IGRT plans was approximated by using
the times for lung SBRT treatments as a surrogate for adrenal
metastases. Lung SBRT treatment times from a single c-arm linac
were collected from the past 12 months.

CT-IGRTFB planning

CT-IGRTBH simulation and segmentation

Each patient was retrospectively replanned to a 3-arc,
volumetric-modulated arc therapy (VMAT) CT-IGRTFB treatment
on a c-arm linac with high-definition multi-leaf collimators. Treatment planning was performed in Eclipse Acuros version 15.6.06
(Varian Medical Systems, Palo Alto, CA, USA) on an isotropic 1.25
mm  1.25 mm  1.25 mm calculation grid. Hemispherical

Daily CTs of patients treated on the MR-linac were not acquired,
therefore the CT-IGRTBH plans were calculated on the same initial
and daily setup breath-hold MRIs used for MRgRTBH planning, with
bulk density overrides. The simulation and fractional segmentation
approved for MRgRTBH was used for the corresponding CT-IGRTBH
plans.

the anatomy of the day (i.e., predicted dose) to evaluate the indication for adaptation, based on target coverage and/or OAR constraints as outlined by the treatment planning directive. If this
predicted dose failed to meet the prescribed metrics, then the plan
was re-optimized and normalized with the adaptive plan used for
patient treatment.
Treatment delivery was performed using real-time tracking for
all patients. The tracking region of interest (ROI) was deformed to
the real-time sagittal cine plane at 4 frames per second. A 3 mm
isotropic expansion from the tracking ROI was used to delineate
the boundary limit of excursion. Gated delivered was performed
such that the beam turned off if greater than 5% of the tracking
ROI was outside this boundary.
In addition to statistics of beam geometry and modulation, the
treatment time was also recorded for all patients included in this
study. Treatment time was calculated from the timestamp of the
patient entering the vault to the completion of radiation delivery
for MRgRTBH fractions.
CT-IGRTFB simulation and segmentation
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counted if it exceeded the dose approved and delivered by the corresponding adaptive MRgRTBH treatment.

CT-IGRTBH planning
To generate the CT-IGRTBH initial plan, the MRI and structure set
for each patient’s initial MRgRTBH plan were imported into Eclipse
and rigidly registered to the GTV, by a board certified medical
physicist, to the previously calculated CT-IGRTFB plan. The MR
and structure set were assigned as the primary to enable the
previously-used optimization values of the CT-IGRTFB plan as a
starting point for the CT-IGRTBH plan generation. The bulk densities
corresponding to the MRgRTBH plans were used in Eclipse. Bulk
densities included tissue (1 g/cc), air (0.0012 g/cc), and for a subset
of patients bone (1.12 g/cc) and lung (0.260 g/cc). The plans were
then re-optimized to meet all of the original prescription constraints and normalized to either full target coverage or until maximum tolerance was reached for a single OAR.
The daily setup BH MRIs for the five treatment fractions were
imported into Eclipse along with the structure sets that were generated and approved during on-table adaptation. The fractional
MRIs were registered based on GTV alignment to the initial CTIGRTBH plans just as described. After assigning bulk densities consistent with the initial CT-IGRTBH plans, the initial plan was recalculated, without re-optimization, on the anatomy of the day
yielding the predicted CT-IGRTBH dose for targets and OARs.

Statistical analysis
Differences in target volume metrics between the initial
MRgRTBH plan and both the CT-IGRTBH and CT-IGRTFB plans were
evaluated for target coverage (TC) (PTV V100%/VPTV and GTV
V100%/VGTV), relative dose to 95%, 90%, 80% and mean PTV and
GTV volumes (i.e., D95%/DRx, D90%/DRx, D80%/DRx, and Dmean/DRx),
homogeneity index (HI) (PTV D2%/D98%), prescription isodose to target volume (PITV) ratio (i.e., volume of the 100% isodose line/VPTV),
low dose conformity (D2cm) (i.e., maximum dose within 2 cm in
any direction from the PTV), and gradient (R50%) (i.e., volume of
the 50% isodose line/VPTV). Additional metrics evaluated were the
mean ipsilateral kidney dose and the doses to 0.5 cc (D0.5cc) of
the GI OARs: small bowel, large bowel, duodenum and stomach.
Statistical analysis was performed on Origin software (OriginLab, Northampton, Massachusetts, USA). A Wilcoxon signedrank test for non-normal distributions was used to assess the statistical differences between MRgRTBH and CT-IGRTBH and between
MRgRTBH and CT-IGRTFB. Differences were not assessed between
the CT-IGRTFB and CT-IGRTBH plans, as this has been previously
reported in the literature. Because the distribution of metrics was
skewed, median values are given with their interquartile (Q2-Q3)
range (IQR). Statistically significant difference was taken as
p < 0.05.

Indication for adaptation CT-IGRTBH and MRgRTBH
OAR and target coverage metrics were compared between the
adaptive MRgRTBH dose, predicted MRgRTBH dose, and predicted
CT-IGRTBH dose. Daily fractions that would have violated the OAR
constraints or delivered a reduction in target coverage (to the relative D95%/DRx dose to the PTV or GTV), were counted and the frequency of violations calculated as a percent of constrained
fractions. An exception was made for the mean ipsilateral kidney.
The ipsilateral kidney was intentionally violated during adaptation
on some fractions at the physician’s direction to prioritize target
coverage. Therefore, an ipsilateral kidney violation was only

Results
The target volumes and dosimetric metrics for conformality,
coverage, organs at risk, and degree of modulation across the 20
patients are displayed in Table 1 for initial MRgRTBH (n = 20 plans)
versus CT-IGRTBH (n = 20 plans) and CT-IGRTFB (n = 20 plans). There
was a statistically significant decrease (p < 0.01) in median PTV
volumes for CT-IGRTBH at 48.9 cc (IQR: 33.1–79.0 cc) versus

Table 1
Comparison of median (and interquartile range) target volume, conformality, coverage, organ-at-risk dose and modulation between the initial plans for breath-hold MR-guided
radiotherapy (MRgRTBH) versus both breath-hold and free-breathing CT image-guided radiotherapy (CT-IGRTBH and CT-IGRTFB).
Metric

Metric unit

MRgRTBH

CT-IGRTBH

p value

CT-IGRTFB

Target

p value

PTV volume
cc
53.6
(37.1–86.1)
48.9
(33.1–79.0)
p < 0.01
91.9
(45.0–135.4)
p < 0.01
GTV or ITV volume
cc
24.6
(14.0–38.5)
21.2
(11.6–34.7)
p < 0.01
43.4
(16.6–69.2)
p < 0.01
Conformality
PITV
V100% Rx iso/VPTV
1.03
(0.98–1.08)
1.03
(0.95–1.11)
NS
0.95
(0.92–1.02)
p < 0.01
Homogeneity index
PTV at D2%/D98%
1.43
(1.29–2.02)
1.33
(1.25–1.50)
p < 0.01
1.67
(1.28–2.18)
NS
R50%
V50% Rx iso/VPTV
3.99
(3.58–4.28)
3.51
(3.13–3.90)
p < 0.01
3.22
(3.02–3.39)
p < 0.01
Max D2cm
% of DRx @ 2 cm from PTV
57.2
(52.2–60.8)
55.4
(53.1–56.4)
NS
57.4
(55.5–61.7)
NS
Coverage
PTV coverage
VPTV at 100% Rx/VPTV
0.95
(0.88–0.95)
0.96
(0.92–0.99)
p < 0.01
0.93
(0.87–0.97)
NS
GTV or ITV coverage
VGTV at 100% Rx/VGTV
1.00
(0.97–1.00)
1.00
(1.00–1.00)
p < 0.01
1.00
(0.96–1.00)
NS
PTV D95%
% of Rx
1.00
(0.83–1.00)
1.02
(0.97–1.07)
p < 0.01
0.98
(0.69–1.03)
NS
PTV D90%
% of Rx
1.02
(0.97–1.03)
1.05
(1.02–1.11)
p < 0.01
1.02
(0.90–1.05)
NS
PTV D80%
% of Rx
1.06
(1.05–1.08)
1.07
(1.06–1.13)
NS
1.06
(1.05–1.08)
NS
PTV Dmean
% of Rx
1.13
(1.11–1.16)
1.12
(1.09–1.17)
NS
1.08
(1.07–1.13)
p < 0.01
GTV or ITV D95%
% of Rx
1.08
(1.05–1.13)
1.07
(1.06–1.12)
NS
1.06
(1.03–1.10)
p = 0.045
GTV or ITV D90%
% of Rx
1.10
(1.09–1.17)
1.08
(1.06–1.13)
NS
1.08
(1.04–1.11)
p = 0.02
GTV or ITV D80%
% of Rx
1.14
(1.11–1.20)
1.09
(1.08–1.15)
NS
1.10
(1.06–1.13)
p < 0.01
GTV or ITV Dmean
% of Rx
1.20
(1.15–1.23)
1.14
(1.12–1.19)
NS
1.12
(1.09–1.15)
p < 0.01
Organs at Risk
Large bowel D0.5cc
Gy
18.4
(15.0–21.9)
15.4
(13.5–21.6)
p = 0.02
21.5
(15.6–24.5)
NS
Small bowel D0.5cc
Gy
13.9
(3.2–29.9)
6.4
(1.4–24.5)
NS
19.7
(9.3–31.9)
p = 0.04
Duodenum D0.5cc
Gy
18.2
(10.9–22.0)
14.4
(10.2–21.0)
p < 0.01
23.5
(6.5–30.6)
NS
Stomach D0.5cc
Gy
24.6
(18.4–33.4)
22.1
(13.7–32.8)
NS
24.0
(19.5–32.7)
NS
Ipsilateral kidney
Gy
7.1
(5.3–9.5)
5.1
(3.1–8.0)
p < 0.01
7.5
(6.0–9.7)
NS
Dmean
Modulation
Beams
number
17
(14–18)
3 arcs
3 arcs
Segments
segments or arc degrees
46
(40–57)
224o
(217-225°)
224o
(217-225°)
Total treatment time
min
64
(30–128)
32
(22–72)
(with full range)*
Note: Planning target volume (PTV), gross tumor volume (GTV), internal target volume (ITV), prescription isodose to target volume (PITV), homogeneity index (HI),
gradient (R50%), low dose conformity (D2cm), dose to at least 95% of volume (D95%), dose to at least 90% of volume (D90%), dose to at least 80% of volume (D80%), mean
dose (Dmean), maximum dose to 0.5 cc of volume (D0.5cc), second quartile (Q2), third quartile (Q3)
104

Downloaded for Anonymous User (n/a) at Baptist Health South Florida from ClinicalKey.com by Elsevier on January 12,
2022. For personal use only. No other uses without permission. Copyright ©2022. Elsevier Inc. All rights reserved.

Radiotherapy and Oncology 166 (2022) 101–109

L.L. Rodriguez, R. Kotecha, M.C. Tom et al.

18.2 Gy, p < 0.01) and the mean ipsilateral kidney (5.1 vs 7.1 Gy,
p < 0.01). There were only marginal decreases in D0.5cc to the small
bowel and the stomach. MRgRTBH exhibited a significant 42%
reduction in D0.5cc (p = 0.04) to the small bowel compared to CTIGRTFB (13.9 vs 19.7 Gy) and marginal reductions to the ipsilateral
kidney, duodenum and large bowel.
A visual representation of the loss of low dose conformality was
observed in Fig. 3 for the larger targets in CT-IGRTFB (Fig. 3C) compared to the MRgRTBH and CT-IGRTBH plans (Fig. 3A and 3B),
though in the aggregate, D2cm was statistically equivalent between
the three treatment techniques. A reduction in the OAR-to-PTV
proximity was observed in Fig. 3 with a greater increase in the volume of overlap between the PTV (cyan ROI) and small bowel (blue
ROI) in CT-IGRTFB (Fig. 3F) compared to MRgRTBH and CT-IGRTBH
plans (Fig. 3D and 3E). Note that the smaller GTVs for the BH plans
do not extend into this axial slice, while the larger ITV is shown on
the CT-IGRTFB plan (green ROI).
Table 2 displays the indication for adaptation evaluated from
the CT-IGRTBH (n = 95 fractions) and MRgRTBH (n = 95 fractions)
predicted dose (i.e., initial plan calculated on anatomy of the
day). Ninety-five fractions were available for analysis, due to one
patient not completing treatment. Table 2 quantifies the frequency
of violations from the OAR constraints (Table A2) and coverage
reductions (for PTV and GTV D95%/DRx) from the initial plan, for
all patient’s fractions. Note that 22 of the 95 MRgRTBH fractions
were not adapted due to predicted dose meeting constraints. In
total, the CT-IGRTBH plans had a 71.8% frequency of indications
for adaptation compared to MRgRTBH plans at 83.0%. However,
the predicted frequency of D95% coverage reductions was higher
on initial CT-IGRTBH plans (27.3%) compared to predicted MRgRTBH
(22.1%). Note that the MRgRTBH adaptive dose had more frequent
coverage reductions (average 27.0%) than MRgRTBH predicted dose
(22.1%) to prevent constraint violations to the luminal GI OARs (incidence 0%). The CT-IGRTBH predicted 44.5% OAR constraint violations, compared to MRgRTBH dose at 60.9%.
An example of the advantage of adaptation over the predicted
CT-IGRTBH dose (Fig. 4A) and predicted MRgRTBH dose (Fig. 4B) versus the adaptive MRgRTBH dose (Fig. 4C) on the fractional MRI of
the day is shown. The D0.5cc stomach constraint of 35 Gy was violated at 36 Gy (Fig. 4A) and 47 Gy (Fig. 4B) respectively, with a PTV
V100% of only 59% (Fig. 4A, 4B) for both. The adaptive MRgRTBH
resulted in a PTV and GTV V100% of 74% and 92%, while reducing
the stomach and small bowel dose below constraints.

MRgRTBH at 53.6 cc (IQR: 37.1–86.1 cc). There was a statistically
significant increase (p < 0.01) in median PTV volumes for CTIGRTFB at 91.9 cc (IQR: 45.0–135.4 cc) over MRgRTBH.
All target coverage metrics in Table 1 are expressed as dose relative to the prescribed dose, to account for the difference in prescriptions (i.e., 40 Gy vs 50 Gy). A statistically significant
(p < 0.01) increase in PTV coverage was observed for CT-IGRTBH
over MRgRTBH for D90% (median 1.05 vs 1.02), D95% (median 1.02
vs 1.00), and relative V100%/VRx PTV TC (0.96 vs 0.95) and GTV TC
(1.00 vs 1.00, where the IQR ranges were 1.00 - 1.00 vs 0.97 1.00). No difference was seen for PTVmean or D80%, nor for GTVmean
or any other GTV metrics.
An increase in PTV coverage, though not statistically significant,
was observed for MRgRTBH compared to CT-IGRTFB for D95%, and TC.
No difference was seen for PTV D90% and D80%. A statistical difference was observed for GTV versus ITV coverage at D90% (median
1.10 vs 1.08), D80% (1.14 vs 1.10), and Dmean (1.20 vs 1.12). The
median of the mean relative PTV dose was also significantly higher
at 1.13 for MRgRTBH versus 1.08 for CT-IGRTFB.
For the BH plans, mean homogeneity and conformality indices
for CT-IGRTBH versus MRgRTBH (Table 1) were 1.33 versus 1.43
for HI (p < 0.01), and 3.51 versus 3.99 for R50% (p < 0.01), but not
statistically different for PITV or maximum dose at 2 cm. While
for the FB versus BH comparison, CT-IGRTFB and MRgRTBH values
were 0.95 and 1.03 for PITV (p < 0.01), 3.22 and 3.99 for R50%
(p < 0.01), but not statistically different for HI or D2cm.
The median MRgRTBH treatment time was 64 minutes (range:
30–28 minutes, n = 95 appointments). The scheduled MRgRTBH
appointment duration was 90 minutes. The median treatment
time for lung SBRT patients (n = 66 appointments) was 32 minutes (range: 22–72 minutes). All lung SBRT patients were FB
with abdominal compression alone, i.e., no intra-fraction monitoring or gating. The scheduled CT-IGRT appointment was 60
minutes for first fraction and 40 minutes for subsequent
fractions.
Fig. 2 displays boxplots of the mean, median and interquartile
ranges of the OAR doses for MRgRTBH, CT-IGRTBH and CT-IGRTFB.
The boxes span the interquartile range (IQR) from quartile 2 to 3,
the median is shown as a horizontal line, and the mean as an
‘‘x.” The whiskers represent 1.5 times the interquartile range, with
outliers not displayed. The CT-IGRTBH plans show a clear improvement over the MRgRTBH plans in maximum dose to 0.5 cc of the
large bowel (15.4 vs 18.4 Gy, p = 0.02), the duodenum (14.4 vs

Fig. 2. Boxplot of the mean, median and interquartile ranges of maximum dose to 0.5 cc volumes for gastrointestinal organs at risk and mean dose to ipsilateral kidney for
initial MRgRTBH, (n = 20 plans), CT-IGRTBH (n = 20 plans), and CT-IGRTFB plans (n = 20 plans) for all 20 patients. Note that the median is denoted as horizontal line, the mean as
an X, and outliers are not displayed. Note: Organ at risk (OAR), MR-guided radiotherapy with breath-hold (MRgRTBH), CT based image-guided radiotherapy with breath-hold
(CT-IGRTBH), CT based image-guided radiotherapy with free-breathing (CT-IGRTFB), dose to 0.5 cc volume (D0.5cc), mean dose (Dmean), Gray (Gy).
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Fig. 3. Comparison of plan quality between MRgRTBH (A, D), CT-IGRTBH (B, E), and CT-IGRTFB (C, F) for two cases. The top row demonstrates the loss of low dose conformality
in maximum dose to 2 cm (D2cm) from the PTV surface due to the larger target size in free-breathing (C) compared to breath-hold (A, B). The bottom row shows increased
overlap of the PTV (cyan) with the proximal small bowel (blue), due to the larger target size in free breathing (F) compared to breath hold (D, E) plans, demonstrating reduced
target coverage in the CT-IGRTFB plan. Note: Organ at risk (OAR), MR-guided radiotherapy with breath-hold (MRgRTBH), CT based image-guided radiotherapy with breathhold (CT-IGRTBH).

in thoracic and abdominal cancers. Gong et al. demonstrated a statistically significant 46% relative increase in PTV volume for esophageal cancers with FB versus deep inspiration breath hold
(DIBH) as well as significant increases in dose to normal lung volumes [13]. Scotti et al. found similarly significant increases in PTV
volume (23%) and normal lung volume doses for FB versus
spirometer-controlled BH for lung cancer [14].
De Kuijer et al. evaluated the amount of superior to inferior
adrenal motion with respiration through 4DCT to be 8.7 ± 4.2 mm
for FB versus 2.4 ± 1.5 mm for Active Breathing Control (ABC) BH,
although the overall margin was not statistically significant across
11 patients between the two techniques [8]. Our study, which
applied a consistent 5 mm PTV expansion margin for all plans,
did show a significant 71% increase (p < 0.05) in PTV volume for
CT-IGRTFB over MRgRTBH techniques, due to the need for an ITV
with FB. While de Kuijer et al. explored the overall motion envelope for adrenal metastases, the dosimetric difference due to the
increase in PTV volume was not evaluated. Surprisingly, we also
found a significant 9.6% decrease (p < 0.01) in median CT-IGRTBH
PTV and GTV size compared to MRgRTBH which should have had
exactly the same volumes.
The transfer of segmentation from ViewRay to Eclipse caused
discrepancies due to masking of the ROI between the two software
systems, so that partially filled voxels were truncated from all contours. This creates a limitation to our ability to compare the initial
BH plan volumes, but possibly also the doses, as targets and OARs
would be smaller and further apart on the CT-IGRTBH plans, which
were approximated on the simulation MRIs. The contours on the
daily fraction MRIs were also affected by segmentation difference
upon being imported into Eclipse, resulting in potentially fewer
OAR constraint violations in the CT-IGRTBH arm.
GTV coverage was significantly better (p < 0.05) for MRgRTBH
than CT-IGRTFB at nearly all dose levels, possibly due to the significantly larger size of the ITV. The planning techniques for all plans
in this study included a minimum relative dose of 120% to the
gross disease with the hotspot driven to 130–140% of the prescription dose. Because increased ablative dose has been previously

Discussion
To the best of our knowledge, this is the first report quantitatively evaluating the indication for adaptive breath-hold MRguided radiotherapy compared to the standard treatment technique of CT-based image guided radiotherapy in the stereotactic
ablation of adrenal malignancies. To this end, we investigated its
impact on target volumes size and dosimetric qualities of coverage,
conformality, and gastrointestinal luminal sparing.
Other studies have demonstrated BH compared to FB reduces
the overall target volume and amount of irradiated normal tissues
Table 2
Indication for adaptation as evidenced by frequency of organ-at-risk violations and
reductions in target coverage for the predicted CT-IGRTBH plans with respect to the
predicted and adapted MRgRTBH plans. (n = 19 patients for 5 fractions).
Frequency of constraint violations
OAR metric

CT-IGRTBH
predicted
dose

MRgRTBH
predicted
dose

MRgRTBH
adaptive
dose

Large Bowel (D0.5 cc)
Small Bowel (D0.5 cc)
Duodenum (D0.5 cc)
Stomach (D0.5 cc)
Dmean Kidney (ipsilateral)
Total violations for subset
of OAR constraints

4.4%
2.4%
12.9%
18.9%
5.9%
44.5%

0%
4.7%
14.3%
27.8%
14.1%
60.9%

0%
0%
0%
0%
0%
0%

Frequency of coverage reductions from initial plan
Target metric
CT-IGRTBH
MRgRTBH
MRgRTBH
predicted
predicted
adaptive
dose
dose
dose
PTV D95%/DRx
14.7%
5.3%
13.7%
GTV D95%/DRx
12.6%
16.8%
13.7%
Total coverage reductions 27.3%
22.1%
27.0%
Total indications for
71.8%
83.0%
N/A
adaptation
Note: CT based image-guided radiotherapy with breath-hold (CT-IGRTBH),
MR-guided radiotherapy with breath-hold (MRgRTBH), organ at risk (OAR),
dose to 0.5 cc (D0.5cc), mean dose (Dmean), dose to at least 95% of volume
(D95%), prescription dose (DRx)
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clinical practice to obtain at least two confirmatory breath hold
scans to calculate the CT-IGRTBH ITV. Such an approach was not
accounted for in this study, and therefore our results underestimate the target volume and overestimate plan quality for the CTIGRTBH technique. Continuous intrafraction motion management
could be carried out in CT-based technologies, however limited
reporting for adrenal BH studies on CT-IGRT have been demonstrated (i.e., 3 of 28 studies in a recent review published last year
by Chen et al.) [1,2,3,22].
Respiratory-gated treatments also increase treatment time. Our
results showed a 50% relative reduction in the total fractional
treatment time with non-gated VMAT. The increase in treatment
time for MRgRTBH includes delays due to respiratory or breath hold
maneuver changes, in addition to delays due to internal anatomical
changes potentially requiring 3D volumetric re-imaging and repositioning. CT-IGRT systems are unlikely to detect internal changes
and could risk delivering ablative doses to sensitive OARs.
As has been previously published, online adaptive radiotherapy
is known to reduce OAR doses and improve target coverage [6]. Our
results for the MRgRTBH arm are consistent with previous findings.
Without adaptation, the GI OARs would have received higher than
prescribed doses as demonstrated by the 60.9% OAR violations for
the predicted MRgRTBH dose. Of note is that the CT-IGRTBH demonstrated marginally fewer OAR violations (44.5%) on the anatomy of
the day, due to the steeper gradient for VMAT over step-and-shoot
IMRT. The more frequent coverage reductions for the CT-IGRTBH
plans is a result of the lack of robustness to the target deformations
within steep and conformal dose gradients of VMAT. The high frequency (71.8%) of indication for adaptation for the CT-IGRTBH arm
is likely to have been undetected without daily soft tissue imaging.
Greater frequencies in the indication for adaptation in each arm
would have resulted from including all OAR constraints
(Table A2) for each patient, however the heterogeneous requirements of the clinical trials involved made this effort prohibitive. It
is uncertain to what extent the use of bulk densities affected the frequency of the indication for adaptation in the CT-IGRTBH arm.
A further limitation of our study is that 4DCT was performed
without any abdominal compression. Therefore our values for

shown to be favorable in terms of local control and overall survival
in adrenal metastases [1], the difference in the amount of ablative
dose coverage observed in this study is anticipated to translate into
favorable clinical outcomes for adaptive MRgRTBH, without
increased risk to the OARs [1,17,18], but further investigation
through prospective clinical trials is warranted.
In our study, the CT-IGRTBH plan demonstrated the advantage of
VMAT over MRgRT IMRT plans in terms of target coverage, OAR
sparing, homogeneity and of course R50% gradient. This advantage
was largely lost in the CT-IGRTFB plans, which exhibited a significant increase in dose to the small bowel, significant decreases in
mean PTV and most GTV coverage metrics, and a loss in homogeneity, due to the large ITV. Interestingly, the R50% gradient and the PITV
are both significantly better, but both metrics are found by dividing
by the very large ITV volume. Hoffman et al., in a retrospective analysis of 277 protocol-acceptable SBRT lung plans, showed a predictable inverse relationship between the value of R50% and the
volume of the PTV for volumes less than 85 cc [19]. This was supported by Desai et al., who derived an analytical expression to calculate the theoretical minimum values of R50% with a knowledge of
the radius and surface area of the PTV [20]. Hoffman et al. and Desai
et al. predict a lower theoretical R50% value for the larger PTV volumes (median 91.9 cc) in CT-IGRTFB, due to the need for an ITV, than
for the smaller PTVs (53.6 cc) in MRgRTBH. The Desai model assumes
a spherical PTV, which was not evaluated for our study.
An advantage of MRgRT over CT-IGRT is that MR-guidance
enables real-time tumor tracking and gating for each BH maneuver
up to eight frames per second during the treatment delivery. For
CT-IGRTFB, treatment planning is reliant on a single respiratory
cycle acquired during 4DCT simulation which may not be representative of the respiratory motion at the time setup and delivery
[8,15] and CT-IGRTBH relies on a snapshot of the patient’s anatomy
at the time of simulation. While surrogate-based and/or fiducial
tracking can be employed on CT-IGRTBH based planning and guidance, a larger overall uncertainty in the correlation to the adrenal
tumor would be associated with this technique versus MRgRTBH
[21] and Chen et al. has shown that BH techniques are not standard
for CT-IGRT [1]. For soft tissue targets in the abdomen, it is routine

Fig. 4. Example of the indication for online adaptation quantified by recalculating the initial plan on the anatomy of the day, displayed for CT-IGRTBH (A) and MRgRTBH (B) for
a single treatment fraction, in addition to the clinical online adaptive MRgRTBH plan (C) created and delivered for this fraction. Note: CT based image-guided radiotherapy
with breath-hold (CT-IGRTBH), MR-guided radiotherapy with breath-hold (MRgRTBH), relative volume of the target covered by 100% of the prescription dose (V100%),
maximum dose to 0.5 cc of the organ-at-risk (D0.05 cc), Gray (Gy).
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ITV may be overestimated. Another potential limitation of this
work is the retrospective nature of segmentation and treatment
planning. Any inter-observer variability was minimized through
peer review and editing of segmentation by two radiation oncologists. All CT-IGRTFB plans were reviewed for clinical acceptability
by a medical physicist and radiation oncologist.
Another limitation of this study is the clinical impact of our
results. The amount of normal tissue sparing for breath-hold was
statistically significant compared to CT-IGRTFB. The VMAT CTIGRTBH plan shows significantly better coverage and homogeneity
than the IMRT MRgRTBH plans. And adaptive MRgRT can treat with
far fewer OAR constraint violations, but the translation into clinical
outcomes at this time is unknown. Future work will be required to
assess the clinical local control and toxicity between the two
approaches.
While two treating prescriptions were utilized in this study (e.g.,
40 Gy and 50 Gy), the majority of patients were treated at 50 Gy (i.e.,
70%). The analysis performed enabled independence of prescription
(i.e., coverage normalized to respective prescription). The amount of
irradiated normal tissues was found to be dependent on the size of
the treatment volume (i.e., free breathing vs breath hold) and technique (i.e., IMRT vs VMAT) with minor contributions from the overall
prescription. If a patient was planned for 40 Gy on the MRgRTBH
course, then the same parameters of target coverage goals and OARs
were utilized for CT-IGRTBH and CT-IGRTFB.
The results of this study may in fact overestimate the amount of
coverage clinically achievable in CT-IGRT for FB or BH. The CT-IGRT
target coverage was artificially higher than clinically acceptable, due
to the fact that the same GI PRV was utilized in all arms. In reality, the
spatial gradient within overlapping GI PRV to PTV would need to be
more conservatively positioned for actual clinical CT-IGRT, since
daily online adaptive radiotherapy would not be available on the
c-arm platform. Our approach of using the same GI PRV was only
to investigate the dosimetric differences due to the ITV versus BH
approach and the BH VMAT vs IMRT techniques, irrespective of
online adaptive versus conventional delivery techniques. Online
adaptive radiotherapy was used for all adrenal MRgRTBH treatments
due to the aforementioned ablative doses in proximity to GI OARs.
In conclusion, initial plans for VMAT CT-IGRTBH were shown to
be dosimetrically superior in target coverage, conformality, and
OAR sparing to the large bowel, duodenum, and ipsilateral kidney
versus IMRT MRgRTBH. However, the majority of fractions had OAR
constraint violations when the initial CT-IGRTBH plans were calculated on the anatomy of the day. MR-guided adaptive radiotherapy
enabled no OAR violations to the luminal GI organs. The highly
conformal CT-IGRTBH plans were less robust to interfractional target changes, compared to MRgRTBH coverage. The dosimetric
advantages of VMAT were lost when applied to the standard free
breathing ITV-approach of CT-based IGRT. Compared to CTIGRTFB, MRgRTBH enabled significant reductions in target volumes,
marginally improved PTV coverage, and significant improvements
in GTV coverage and small bowel sparing.
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Table A1
Patient and tumor characteristics
Characteristic

N (Range)

Number of patients
20
Median age in years at adrenal treatment
60 (27–75)
Sex
Male
10
Female
10
ECOG performance status
0
2
1
15
2
2
3
1
Laterality
Left
11
Right
9
Primary Tumor type
Bladder
1
Breast
1
Esophagus
1
Lung
17
Histology
Adenocarcinoma
13
Adenosquamous NSCC
1
Angiosarcoma
1
Infiltrating Ductal
1
Carcinoma
Squamous Cell Carcinoma
1
Small Cell Carcinoma
2
Urothelial Carcinoma
1
AJCC stage at primary diagnosis
IA
1
IB
2
IIA
0
IIB
1
III
2
IIIA
1
IIIB
3
IIIC
1
IV
9
AJCC stage at adrenal treatment
IV
20
Prescribed dose
Median (Range) in Gy
50 (40–50)
Fractions
5
Note: number (N), Eastern Cooperative Oncology Group (ECOG), Non-small
cell carcinoma (NSCC), American Joint Committee on Cancer (AJCC), Gray
(Gy)
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Table A2
Overview of OAR constraints for patients in this study (n = 20 patients  5 fractions).
Organ at risk

Metric

Median

Range

Esophagus

D0.03cc
35
30
35
D5cc
27.5
27.5
27.5
Stomach
D0.03cc
39
33
40
D0.5cc
35
33
35
26.5
26.5
26.5
D5cc
Duodenum
D0.03cc
38
34.5
40
D0.5cc
33
30
35
Large Bowel
D0.03cc
35
25
43
D0.5cc
33
30
38
D30cc
24
24
24
Small Bowel
D0.03cc
36.5
34.5
40
D0.5cc
33
30
35
D30cc
24
24
24
Kidneys
D200cc
17.5
17.5
17.5
Dmean (Ipsilateral)
8
5
10
Dmean (Contralateral)
6
3
10
Spinal Canal
D0.03cc
28
20
45
D0.35cc
22
22
22
D1.2cc
15.5
15.5
15.5
Liver
D700cc
21
21
21
13
10
18
Dmean
Skin
D0.03cc
38.5
38.5
38.5
D10cc
36.5
36.5
36.5
Note: Organ at risk (OAR), dose to 0.03 cc volume (D0.03cc), dose to 5 cc (D5cc),
dose to 0.5 cc (D0.5cc), dose to 30 cc (D30cc), dose to 200 cc (D200cc), mean
dose (Dmean), dose to 0.35 cc (D0.35cc), dose to 1.2 cc (D1.2cc), dose to 700 cc
(D700cc), dose to 10 cc (D10cc)

References
[1] Chen WC, Baal JD, Baal U, Pai J, Gottschalk A, Boreta L, et al. Stereotactic Body
Radiation Therapy of Adrenal Metastases: A Pooled Meta-Analysis and
Systematic Review of 39 Studies with 1006 Patients. Int J Radiat Oncol Biol
Phys 2020;107:48–61. https://doi.org/10.1016/j.ijrobp.2020.01.017.
[2] Oshiro Y, Takeda Y, Hirano S, Ito H, Aruga T. Role of radiotherapy for local
control of asymptomatic adrenal metastasis from lung cancer. Am J Clin Oncol
2011;34:249–53. https://doi.org/10.1097/COC.0b013e3181dbb727.
[3] Buergy D, Rabe L, Siebenlist K, et al. Treatment of adrenal metastases with
conventional or hypofractionated image-guided radiation therapy - patterns
and outcomes. Anticancer Res 2018;38(8):4789–96. https://doi.org/10.21873/
anticanres.12788.
[4] König L, Häfner MF, Katayama S, Koerber SA, Tonndorf-Martini E, Bernhardt D,
et al. Stereotactic body radiotherapy (SBRT) for adrenal metastases of
oligometastatic or oligoprogressive tumor patients. Radiat Oncol 2020;15.
https://doi.org/10.1186/s13014-020-1480-0.
[5] Chance WW, Nguyen Q-N, Mehran R, Welsh JW, Gomez DR, Balter P, et al.
Stereotactic ablative radiotherapy for adrenal gland metastases: factors
influencing outcomes, patterns of failure, and dosimetric thresholds for
toxicity. Pract Radiat Oncol 2017;7:e195–203. https://doi.org/10.1016/j.
prro.2016.09.005.
[6] Palacios MA, Bohoudi O, Bruynzeel AME, van Sörsen de Koste JR, Cobussen P,
Slotman BJ, et al. Role of daily plan adaptation in MR-guided stereotactic
ablative radiation therapy for adrenal metastases. Int J Radiat Oncol Biol Phys
2018;102:426–33. https://doi.org/10.1016/j.ijrobp.2018.06.002.

109

Downloaded for Anonymous User (n/a) at Baptist Health South Florida from ClinicalKey.com by Elsevier on January 12,
2022. For personal use only. No other uses without permission. Copyright ©2022. Elsevier Inc. All rights reserved.

